Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a)

被引:3
|
作者
Schwarz, Andrea [1 ,2 ,3 ,4 ,5 ]
Demuth, Ilja [1 ,2 ,3 ,4 ,6 ]
Landmesser, Ulf [7 ,8 ,9 ]
Haghikia, Arash [7 ,8 ,9 ]
Konig, Maximilian [1 ,2 ,3 ,4 ]
Steinhagen-Thiessen, Elisabeth [1 ,2 ,3 ,4 ,10 ]
机构
[1] Charite Univ Med Berlin, Dept Endocrinol & Metab Dis, Including Div Lipid Metab, Augustenburger Pl 1, D-13353 Berlin, Germany
[2] Charite Univ Med Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[3] Free Univ Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[4] Humboldt Univ, Biol Aging Working Grp, Augustenburger Pl 1, D-13353 Berlin, Germany
[5] Charite Univ Med Berlin, Div Cardiol, Dept Pediat, Berlin, Germany
[6] BCRT Berlin Inst Hlth Ctr Regenerat Therapies, Berlin, Germany
[7] Charith Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany
[8] Charite Univ Med Berlin, Dept Cardiol, Campus Benjamin Franklin, Berlin, Germany
[9] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany
[10] Univ Rostock, Inst Clin Chem & Lab Med, Rostock, Germany
关键词
LDL-cholesterol; Treatment goal achievement; Familial hypercholesterolemia; Lipoprotein (a); Coronary artery disease; Lipid-lowering treatment; Family history; LIPID-MODIFYING THERAPY; CARDIOVASCULAR RISK; HEART-DISEASE; ASSOCIATION; EZETIMIBE; HISTORY; ATORVASTATIN; SIMVASTATIN; GUIDELINE; DIAGNOSIS;
D O I
10.1186/s12944-022-01708-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background Although potent lipid-lowering therapies are available, patients commonly fall short of recommended low-density lipoprotein cholesterol (LDL-C) levels. The aim of this study was to examine the relationship between familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] and LDL-C goal attainment, as well as the prevalence and severity of coronary artery disease (CAD). Moreover, we characterized patients failing to meet recommended LDL-C goals. Methods We performed a cross-sectional analysis in a cohort of patients undergoing cardiac catheterization. Clinical FH was determined by the Dutch Clinical Lipid Network Score, and Lp(a) >= 50 mg/dL (approximate to 107 nmol/L) was considered elevated. Results A total of 838 participants were included. Overall, the prevalence of CAD was 72%, and 62% received lipid-lowering treatment. The prevalence of clinical FH (probable and definite FH) was 4%, and 19% had elevated Lp(a) levels. With 35%, LDL-C goal attainment was generally poor. Among the participants with clinical FH, none reached their LDL-C target. Among patients with elevated Lp(a), LDL-C target achievement was only 28%. The prevalence and severity of CAD were higher in participants with clinical FH (86% prevalence) and elevated Lp(a) (80% prevalence). Conclusion Most participants failed to meet their individual LDL-C goals according to the ESC 2016 and 2019 guidelines. In particular, high-risk patients with clinical FH or elevated Lp(a) rarely met their target for LDL-C. The identification of these patients and more intense treatment approaches are crucial for the improvement of CAD primary and secondary prevention.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events
    Martin, RL
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (04): : 525 - 525
  • [42] Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study
    Gouni-Berthold, Ioanna
    Schaper, Frank
    Schatz, Ulrike
    Tabbert-Zitzler, Anja
    Fraass, Uwe
    Sauer, Sarah
    Ray, Kausik K.
    ATHEROSCLEROSIS PLUS, 2022, 50 : 10 - 16
  • [43] Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol
    deGoma, Emil M.
    Leeper, Nicholas J.
    Heidenreich, Paul A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (01) : 49 - 55
  • [44] Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics
    Chua, Yung-An
    Nazli, Sukma Azureen
    Rosman, Azhari
    Kasim, Sazzli Shahlan
    Ibrahim, Khairul Shafiq
    Radzi, Ahmad Bakhtiar Md
    Kasim, Noor Alicezah Mohd
    Nawawi, Hapizah
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2023, 30 (10) : 1317 - 1326
  • [45] Perspectives on low-density lipoprotein cholesterol goal achievement
    Catapano, Alberico L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (02) : 431 - 447
  • [46] Low-Density Lipoprotein Cholesterol in Patients With Homozygous Familial Hypercholesterolemia Who Participated in Sequential Studies of Alirocumab and Evinacumab
    Raal, Frederick J.
    Rosenson, Robert S.
    Kolovou, Genovefa
    Harada-shiba, Mariko
    Mitchenko, Olena
    Rubba, Paolo
    Ali, Shazia
    Banerjee, Poulabi
    Khilla, Nagwa
    McGinniss, Jennifer
    Pordy, Robert
    Blom, Dirk J.
    CIRCULATION, 2021, 144
  • [47] REDUCTION IN PLASMA LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND URINARY MEVALONIC ACID BY LOVASTATIN IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    PAPPU, AS
    ILLINGWORTH, DR
    BACON, S
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1989, 38 (06): : 542 - 549
  • [48] Effects of colestimide in addition to atorvastatin on low-density lipoprotein (LDL) cholesterol in patients with heterozygous familial hypercholesterolemia (FH)
    Kawashiri, M
    Higashikata, T
    Tsuchida, M
    Takata, M
    Katsuda, S
    Miwa, K
    Inazu, A
    Mabuchi, H
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 172 - 172
  • [49] Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia
    Won, Jane I.
    Zhang, Jun
    Tecson, Kristen M.
    McCullough, Peter A.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2017, 18 (01) : 21 - 28
  • [50] Mutations in the low-density lipoprotein receptor gene in Chinese familial hypercholesterolemia patients
    Mak, YT
    Pang, CP
    Tomlinson, B
    Zhang, J
    Chan, YS
    Mak, TWL
    Masarei, JRL
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (10) : 1600 - 1605